The probability of mutation of ovarian cancer anti-cancer gene is clear

May 6, Fudan University Affiliated Cancer Hospital held a presentation of ovarian cancer research results, professor Wu Xiaohua led the ovarian cancer research team for many years, the first multi-center ovarian cancer embryo clinical study found that in China's ovarian cancer patients, the risk of BRCA1 and BRCA2 gene mutation in the body as high as 28.5%. The research shows that BRCA gene testing can not only be an important reference data for early screening of ovarian cancer, but also have great clinical significance for ovarian cancer prevention and patients' late drug use. The results have been published in the International Journal of Gynaecological Oncology (IGCS), the official journal of the International Society of Gynaecological Oncology .Wu Xiaohua said that the BRCA gene mutation in human cells is closely related to the occurrence of ovarian cancer, of which BRCA1 and BRCA2 are anti-cancer genes, if the BRCA mutation, it will lose the ability to inhibit the occurrence of tumors, and lead to the proliferation of cancer cells. The lifetime risk of ovarian cancer in the general population is about 1%, but the risk of ovarian cancer in carriers of BRCA1 gene mutation can be as high as 40%, and the risk of ovarian cancer in carriers of BRCA2 gene mutation can be increased to 11% to 18%. This study provides a theoretical basis and basis for further developing precision treatment plan and establishing BRCA gene testing consensus in ovarian cancer patients in China. On the basis of the pre-BRCA1 and BRCA2 gene mutation studies, the ovarian cancer research team of Fudan University Affiliated Oncology Hospital used multi-gene testing to detect the periter blood and tumor tissue of ovarian cancer patients at the same time, and the results showed that in addition to BRCA1 and BRCA2 embryos, In addition to system mutations, their study also found that the risk of ovarian cancer-related BRIP1, RAD50, RAD51 and other gene embryo line, system mutations also accounted for a considerable proportion, its positive test rate from the previous 28.5% (embryo system), about 10 percentage points (embryo system).The study believes that multigene testing can make a more comprehensive assessment of the genetic risk of ovarian cancer patients, detect more genetic ovarian cancer patients, and help to carry out follow-up genetic counseling and family prevention work more effectively. In addition, system testing can provide more information on drug targets and aid in precision treatment.Wu Xiaohua suggested that ovarian cancer patients should do BRCA genetic testing, if a mutation has occurred, their first-level relatives (such as mother and daughter, sisters, etc.) should also be tested to help early screening of potential patients and take preventive measures; "Multigene testing", such as the discovery of BRCA1 or BRCA2 gene mutations, can be taken at about 40 years of age or 45 years of age, such as RAD51 gene mutations, because the risk is reduced, can be taken around 50 years of age preventive measures. (Health Report)